LXW7 (TFA)

934.92

H2O

Cytoskeleton

LXW7 TFA, a cyclic peptide containing Arg-Gly-Asp (RGD), is an integrin alphavbeta3 inhibitor. LXW7 has a high binding affinity to alphavbeta3 integrin with an IC₅₀ of 0.68 uM. LXW7 TFA increases phosphorylation of VEGFR-2 and activation of ERK1/2. Anti-inflammatory effect^[1][2][3]. IC50 & Target: IC50: 0.68 uM (alphavbeta3 integrin)^[1] In Vitro: LXW7 specially binds to alphavbeta3 integrin (K_d=76+/-10 nM). LXW7 binds strongly to alphavbeta3-K562 cells, weakly to alphavbeta5-K562 cells and alphaIIbbeta3-K562 cells, and no binding to K562 cells. LXW7 has great potential as a highly efficient peptide ligand for targeted imaging and drug delivery^[1].
LXW7 acts as a potent and specific endothelial progenitor cells (EPCs) and endothelial cells (ECs) targeting ligand^[2]. In Vivo: LXW7 (100 ug/kg; intravenous injection) significantly lowers infarct volumes and brain water content (BWC) LXW7-treated rats. The LXW7 treatment lowers the expression of pro-inflammatory cytokines^[3].